Trials / Unknown
UnknownNCT00772720
Effects of Raltegravir (Isentress®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers
Study on the Effects of Raltegravir (Isentress®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (estimated)
- Sponsor
- Hospital Clinic of Barcelona · Academic / Other
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Raltegravir is the first of a new antiretroviral class. A better profile of metabolic toxicity is expected. In order to better define its effects, without interference with other drugs, a study on healthy volunteers is warranted.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | raltegravir | raltegravir 400 mg BID for 7 days |
| DRUG | Placebo | Placebo BID for 7 days |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2008-10-15
- Last updated
- 2010-03-31
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT00772720. Inclusion in this directory is not an endorsement.